NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00929981,A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients,https://clinicaltrials.gov/study/NCT00929981,,COMPLETED,"This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability of Medrol in treating contact dermatitis in Indian patients. Patients with contact dermatitis who have been prescribed for Medrol will be enrolled into the study and will be followed up for the resolution of symptoms",YES,"Dermatitis, Contact",DRUG: Tablet Methylprednisolone (4 or 16 mg),"Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit, The signs and symptoms of CD were rated on Physician's Global Assessment (PGA) 5-point scale (range, 0 - 4 scale): 0 - no clinically relevant reaction; 1- macular erythema with induration; 2 - weak (non-vesicular) reaction with erythema, infiltration, and possible papules; 3 - strong (edematous or vesicular) reaction; 4 - extreme (spreading, bullous, ulcerative) reaction. ""Success"" was defined as a score of 0 or 1 and ""failure"" was defined as a score of 2, 3, or 4., Second follow-up visit (Day 5-28)","Treatment Status (Success/Failure) of CD at the First Follow-up Visit, The signs and symptoms of CD were rated on PGA 5-point scale (range, 0 - 4 scale): 0 - no clinically relevant reaction; 1- macular erythema with induration; 2 - weak (non-vesicular) reaction with erythema, infiltration, and possible papules; 3 - strong (edematous or vesicular) reaction; 4 - extreme (spreading, bullous, ulcerative) reaction. ""Success"" was defined as a score of 0 or 1 and ""failure"" was defined as a score of 2, 3, or 4., First follow-up visit (between Day 6 to 10 after start of treatment)|Treatment Status (Success/Failure) of CD at the Third Follow-up Visit, The signs and symptoms of CD were rated on PGA 5-point scale (range, 0 - 4 scale): 0 - no clinically relevant reaction; 1- macular erythema with induration; 2 - weak (non-vesicular) reaction with erythema, infiltration, and possible papules; 3 - strong (edematous or vesicular) reaction; 4 - extreme (spreading, bullous, ulcerative) reaction. ""Success"" was defined as a score of 0 or 1 and ""failure"" was defined as a score of 2, 3, or 4., Third follow-up visit (between Day 6 to 10 after EOT)|Treatment Status (Success/Failure) of CD at the Final Follow-up Visit, The signs and symptoms of CD were rated on PGA 5-point scale (range, 0 - 4 scale): 0 - no clinically relevant reaction; 1- macular erythema with induration; 2 - weak (non-vesicular) reaction with erythema, infiltration, and possible papules; 3 - strong (edematous or vesicular) reaction; 4 - extreme (spreading, bullous, ulcerative) reaction. ""Success"" was defined as a score of 0 or 1 and ""failure"" was defined as a score of 2, 3, or 4., Final follow-up visit (between Day 25 to 35 after EOT)|Change From Baseline in Participant-rated Clinical Severity Score of Lesions at First, Second, Third and Final Follow-up Visits, Participant-rated clinical severity score of lesions rated the severity of all symptoms in the past 24 hours on an 11-point Numerical Rating Scale (NRS) where 0 = No lesions and 10 = Most severe possible lesions., Baseline,First Follow-up(between Day 6-10 of start of treatment),Second(Day 5-28),Third(between Day 6-10 after EOT),Final(between Day 25-35 after EOT)|Change From Baseline in Participant-rated Pruritus Score at First, Second, Third and Final Follow-up Visits, Participant-rated pruritus score of lesions rated the severity of pruritus suffered in the past 24 hours on an 11-point NRS where 0 = no pruritus and 10 = most severe possible pruritus., Baseline,First Follow-up(between Day 6-10 of start of treatment),Second(Day 5-28),Third(between Day 6-10 after EOT),Final(between Day 25-35 after EOT)|Change From Baseline in Investigator-rated Total Signs and Symptoms of CD Score at First, Second, Third and Final Follow-up Visits, Investigator-rated total signs and symptoms score of CD included pruritus, erythema, induration, vesiculation, edema or other specific sign or symptom rated on a 5 point scale of 0 - 4 (0=none, 1=mild, 2=moderate, 3=severe, 4=extreme) with a total score of 0 - 20 (lower score was preferred)., Baseline,First Follow-up(between Day 6-10 of start of treatment),Second(Day 5-28),Third(between Day 6-10 after EOT),Final(between Day 25-35 after EOT)",,Pfizer,,ALL,"CHILD, ADULT, OLDER_ADULT",,80,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,B0121004,2009-09,2010-09,2010-09,2009-06-30,2011-08-03,2019-01-02,"Pfizer Investigational Site, Bangalore, Karnataka, 560 038, India|Pfizer Investigational Site, Mumbai, Maharashtra, 400 058, India|Pfizer Investigational Site, Mumbai, Maharashtra, 421 201, India|Pfizer Investigational Site, Ludhiana, Punjab, 141001, India",
